Welcome to our dedicated page for Scpharmaceutical news (Ticker: SCPH), a resource for investors and traders seeking the latest updates and insights on Scpharmaceutical stock.
scPharmaceuticals Inc. reports news on its cardiorenal pharmaceutical business, including commercialization of FUROSCIX, furosemide formulation development, and intellectual property for SCP-111. Company updates also cover clinical and regulatory disclosures tied to cardiorenal conditions such as heart failure and chronic kidney disease.
Recurring releases include quarterly financial results, business updates, product revenue trends, material agreements, capital-structure actions, governance matters, investor-conference participation, and corporate-status developments affecting SCPH common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
scPharmaceuticals Inc. (SCPH) has launched FUROSCIX®, the first self-administered subcutaneous loop diuretic for chronic heart failure treatment, effective February 20, 2023. The company ended Q4 2022 with $118.4 million in cash and reported a net loss of $9.2 million for the quarter. This represents an increase from $7.3 million in Q4 2021. The company also completed a $50 million stock offering and a $100 million secured debt financing to support FUROSCIX commercialization. Expectations indicate rising operational costs in 2023 for marketing efforts. CEO John Tucker expressed optimism regarding FUROSCIX's potential impact on patient care.